Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Todos Medical is excited to join the B2i Digital family and to attend the ROTH Capital Partners Healthcare Opportunities Conference on October 6th, 2022!
https://b2idigital.com/roth-healthcare-opportunities?utm_campaign=Testimonial%20Campaign&utm_medium=email&_hsmi=228488604&_hsenc=p2ANqtz-99Nx1mvAKxn2UVDPvlkCdvg_ea8_b7IlBl3ZWfGax8hY13fb3wUpWs8HRbG5wXD25igpXH5rzNWdIQJ-1O6fiR8gxYbw&utm_content=228488604&utm_source=hs_email
TOMDF shares closed with 1 million traded....looks like daytraders/HFT's are losing interest now and we're seeing lower highs and lower lows .
"Investors" are getting nervous
TODOS MEDICAL RECEIVES NOTICES OF ALLOWANCE FOR ITS TBIA PAN-CANCER BLOOD DIAGNOSTICS PLATFORM
Proactive - Interviews for investors
5 min audio interview
CEO Gerald Commissiong and Proactive's Stephen Gunnion
https://music.amazon.com.br/podcasts/408ad96c-2a3d-4498-8ac5-ced7a4becb73/episodes/589be71c-fe4b-4ee4-842d-a6fa8ec3a8c1/proactive---interviews-for-investors-todos-medical-receives-notices-of-allowance-for-its-tbia-pan-cancer-blood-diagnostics-platform
I didn't say dilution of shares, what is that anyway?
I was talking value, as in the overall value.
I'll try to explain it to you.
If Todos own 52 % of 3CL and 3CL give away part of their company to raise money then those who participated in the "raise" will now own some of 3CL resulting in a dilution of value to the 52 % held by Todos
Looking good the last 2 days hope this is the start of something
Sounds like a lot of justification going on to allow more dilution.
There likely is a perfectly good reason for spinning off 3CL Pharma but , is it beneficial to Todos shareholders, I certainly would doubt that.
I't's sorta like a public company with a successful service/product spinning it off thru privatization to get a small cut. In other words short term gain by selling off a desirable part of the company.
But then you know the acronym BBB.
....and you can't live on unfulfilled promises either, especially when the shares are getting lower priced every day....even the flippers are moving on
The way I see setting up Crowd Funding for a company 52 % owned by TODOS is that it is dilution. Whether it is bad or good , time will tell. Hopefully there are other better reasons why Todos set up this newco rather than just keep it under the company umbrella.
Creating a private company owned by a public company with possible intentions of having the private company go public eventually.
"Simplex cum tartar"
TOMDF is trending on iHub based on user activity # 38
Absolutely, good stuff , I'm sure TOMDF have many shareholders who share your enthusiasm.
Not always the way it works...I wouldn't use the word "investors" (in a penny stock?) but those who find the company sliding down often get caught holding too long, it's hard to put a proper stop loss in a penny stock.
So we become Bagholders.
Other options are to hold on for good or bad, get all out and move to the next one, average down or sell part of you holdings in thirds or halves...
At this point the bagholders are typically those who held on because they fell in love with the stock and keep on convincing themselves and anyone else who will listen that it's a great longterm investment.
So that's why I'm more interested in Todos as it is now rather that what it could be.
There are thousands of Companies languishing with half developed products that have run out of money in a dead sector.
Actually what I was asking was answered by DDDrey but thanks. I'm not so much interested in promises and plans down the road but rather what is actually happening now
Okay Leslunier, thanks , I will do that
Thanks again DDD
I didn't think so
Are there other or any revenue streams besides Tollovid ($1,000,000 so far)?
What clinical trials are we in now?
What is the testing numbers? Do we know?
Another slow day for the shareprice, it seems that the shares are just trading back and forth between 5 or six broker/dealers, whether they're flipping or we're being covered by HFT's.
At least the stock closed reasonably solid at .018.
We need some real news with some kind of benchmark made or a promise come true. I wouldn't hold my breath on EUA, that is hard to come by unless your name is Pfizer or Moderna
"TOMDF getting closer to some major network coverage. Spoke with two financials arms of MSM this weekend. Long COVID is on their minds big time with Q3 GDP looming, and the JJ Watt post-COVID story on the table as well." GC On Twitter
Whassappenin...light trading today, 2 trades so far
Thanks for asking, Like TODOS aspirin has a natural background,, the active ingredient in aspirin, acetylsalicylic acid works by inhibiting several different chemical processes within the body, including the natural physiological processes causing pain and inflammation.....and interestingly enough Broccoli, cauliflower, cucumber, mushrooms, radishes, spinach, and zucchini all contain high amounts of salicylates. Vegetables from the nightshade family, like eggplant and peppers, also contain salicylates.....
Well spoken!
Monday Big BIG, HUGE money coming into TOMDF. Could be the next $15B Moderna I hear TOMDF is just missing a bunch of products, features, security and users. Oh and a real exchange that has things like SEC compliance.
Chart looking like its almost reached bottom
But maybe that is just institutional investors money propping it up...or maybe daytraders....or HFT's? ...
Who knows anyway.... can be tricky to tell.
One thing is for sure.....
VALUE OF 3CL PROTEASE INHIBITOR SUPPLEMENTATION 1 The Value of 3CL Protease Inhibitor Supplementation in Long Haul Syndrome Patients?
" Thus, based upon the research available to date, there is a strong indication that introducing a regimen of supplementation with a 3CL protease inhibitor early in the symptomatic phase increases the chances of resolving COVID-19 symptoms.
Additional research is needed to better understand the correlation of outcome with
early intervention."
" Over 80% of all respondents found improvement in both COVID and LHS symptoms after taking Tollovid. Results are significant and demonstrate a self-reported benefit to using the supplement for a 5-day course."
" In fact, the majority of LHS patients report that food supplementation is their primary mode to achieve symptom relief. In this publication, we report data from over 100 Acute COVID and LHS patients on the potential benefits of Tollovid, a 3CL protease inhibitor cleanse supplement.
Based upon this analysis, further investigation is warranted in a controlled, prospective clinical trial setting."
https://www.researchgate.net/publication/362791461_VALUE_OF_3CL_PROTEASE_INHIBITOR_SUPPLEMENTATION_1_The_Value_of_3CL_Protease_Inhibitor_Supplementation_in_Long_Haul_Syndrome_Patients_The_Value_of_3CL_Protease_Inhibitor_Supplementation_in_Long_Haul_Sy
A wise man once said " reverse splits never work out I hear." and even GC said we won't do it until the time is right, am I right?
Yet the stock struggles. It's my belief that the shareprice is failing now because there is major disappointment and reluctance to put money into (I wouldn't call it 'investing') the stock. I mean why would anyone buy a struggling penny stock now, when it is preparing to do a reverse split ?
There was an AGM last week but so far I haven't heard if there are any concrete revenue generators or clinical trials active at this point. Promises yes...lots... but I'd like to see something more substantial.
Some would say that things are in the works , do some dd, check the news releases....and I have. And believe it or no it makes me even more unsure.
Appreciate some feedback here , especially from a new poster.
Records are being broken
Tomdf approaching a new 52 week low during trading. Is $0.01 in play next week? hope not...with an r/s coming that might not be good
Day Range Friday : .0196-.015
52 Week Range: .644 - .0103...nice upside potential ?
Are there other or any revenue streams besides Tollovid ($1,000,000 so far)?
What clinical trials are we in now?
What is the testing numbers? Do we know?
CEO on Twitter - It sure is nice that GC gets it done and has a good presence on Twitter, I wonder if TOMDF follow this board.
Todos have been good enough to keep us posted with their plans going forward. Being a relatively new shareholder I think that it's getting a bit confusing with all of the plans the company has versus what has actually already transpired. After a while promised don't make the shareprice stronger since a lot of old news and hopes are already built-in to the shareprice.
I'm getting confused as to what is actually really being done NOW ....we have Tollovid now as a online revenue stream, testing is confusing in that some tests are approved and being used somewhere and clinics are planned , but is testing bringing in revenue now?
And that's another thing. What is actually in clinical testing now as we speak?
Are there other revenue streams that are actually bringing in money Now?
I think most of the action/volume on the shareprice looks like micro penny flippers and HFT's so the shareprice is vulnerable....Press Releases with future plans no longer move it or strengthen it.
I have read the news but still confused.
So the question is are there other or any revenue streams besides Tollovid?
And are we currently actively in a clinical trial?
Board sets new record....1 member has had 44 posts removed from the TOMDF board in 13 days. That's 33.8% of their posts removed, (soon to be 45 or 34.6% of them)
Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
09/27/2022 12:30 PM
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint Independent Data Monitoring Committee agreed that the new targeted study size is appropriate Enrollment now expected to conclude in Q1 2023,
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
08/15/2022 12:30 PM
WARREN, N.J. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial
Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference
05/12/2022 12:30 PM
WARREN, N.J. , May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced a poster presentation at the upcoming American
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
05/11/2022 12:30 PM
WARREN, N.J. , May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial
Medium volume yesterday. Big things coming into TOMDF. Could be the next Pfizer.
Todos is just missing a bunch of proven products, finished raises, and investors.
Needs a real exchange that has more compliance regulations.
Chart looking like its reached bottom a few times, just needs one of the promises to become realized then we may see a pop.
Red earlier you posted an interesting post, "Was there a question about these two analysts that followed...." who were you quoting in the last 6 paragraphs of the post?
JFB sorry you stated that "I especially like the option with the new share structure to bring 100% of 3CL Pharma/Sciences back under Todos ownership."
Where was that written?
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform
September 30, 2022 09:59 ET | Source: Todos Medical Ltd.
https://www.globenewswire.com/news-release/2022/09/30/2526085/0/en/Todos-Medical-Receives-Two-Notices-of-Allowance-from-USPTO-for-AI-Based-TBIA-Pan-Cancer-Blood-Diagnostics-Platform.html
Proposal 4. The reauthorization of the Company’s Board of Directors to effect a reverse split of the Company’s ordinary shares, such that the Board of Directors may effect a reverse split of the Company’s entire share capital share at a ratio within the range from 1-for-2 up to 1-for-500, provided that the Company shall not effect reverse share splits that, in the aggregate, exceed 1-for 500 was approved by the stockholders by the votes set forth in the table below:
For........ ......... Against.......... .... Abstain
261,232,412/.... 44,435,499/.... 4,324,681
So what happened at the TODOS AGM....500:1 split coming?
I just checked the OTCQB and they have many stocks that are over 2 or 3 bucks and more that trade higher....what's the big deal?
If you say it's because institutional investors would want that....not true, many are quite happy if the shareprice is 50 cents or more...lots of room for them to hedge (short) so let's just wait
why do TOMDF have to R/S if they can just grow the price with time and merit. The listing and Financial requirements on the NasDaq are much more stringent too , I would think?
Quinine likely the worst example here since it has awful side effects, can you not find a better example like Penicillin or Nitric Oxide maybe ....see Link
https://investorshub.advfn.com/Nitric-Oxide-generated-and-TCM-Related-Health-Stocks-41481
Beyond Air® To Participate in Three Upcoming Investor Conferences
LifeSci Partners HealthTech Symposium – September 20-21, 2022
Title: Beyond Air (XAIR) Fireside Chat
Date & Time: Wednesday, September 21, 2022, at 12:00 – 12:25pm ET
Moderator: Corey Davis, Ph.D., LifeSci Advisors, LLC
Participant: Steve Lisi, Chairman & CEO, Beyond Air
Location: Virtual
Webcast Link: Link
Ladenburg Thalmann Healthcare Conference – September 29, 2022
Title: Beyond Air (XAIR) Company Presentation
Date & Time: Thursday, September 29, 2022, at 1:30pm – 1:55pm ET
Presenter: Steve Lisi, Chairman & CEO, Beyond Air
Location: Sofitel New York City
Webcast Link: Link
Roth Inaugural Healthcare Opportunities Conference – October 6, 2022
Title: Beyond Air (XAIR) Company Presentation
Date & Time: Thursday, October 6, 2022, (Time - TBD)
Presenter: Steve Lisi, Chairman & CEO, Beyond Air
Location: The Yale Club, New York City
Webcast Link: TBD
https://stockhouse.com/news/press-releases/2022/09/16/beyond-air-xae-to-participate-in-three-upcoming-investor-conferences
GARDEN CITY, N.Y., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced an update to the expectations for U.S. Food and Drug Administration (FDA) approval of LungFit® PH for the treatment of persistent pulmonary hypertension of the newborn, or PPHN. https://www.beyondair.net/news-and-events/press-releases/detail/153/beyond-air-provides-regulatory-update-for-lungfit-ph
How is nitric oxide stored in the human body?
Nitric oxide does not usually exist in its free form in the body due to its unstable nature but reacts with other molecules to form more stable products.
In the blood, nitric oxide has a very short half-life and rapidly oxidises to nitrite. It is then further oxidised with oxyhaemoglobin to produce nitrate. Nitric oxide also reacts directly with oxyhaemoglobin to produce methhaemoglobin and nitrate.
Reactions with cysteine residues in proteins lead to formation of nitrosylated products. Because of its high affinity to sulfhydryl groups (thiols), S-nitrosothiols (RSNOs) are the most common nitrosylated product in plasma.
Nitrate is the main storage form of nitric oxide. It is very stable when compared with other storage forms such as nitrites and RSNOs, which are important carriers and donor molecules of nitric
Beyond Air (XAIR) Investor Presentation - Slideshow
The following slide deck was published by Beyond Air, Inc. in conjunction with this event.
For further details see:
https://static.seekingalpha.com/uploads/sa_presentations/694/87694/original.pdf